fluoxetine has been researched along with Multiple Sclerosis in 18 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Was to evaluate the effect of selective serotonin reuptake inhibitor fluoxetine on the production of cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) by dendritic cells in multiple sclerosis (MS)." | 7.96 | [The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro]. ( Boyko, AN; Krivenko, LV; Melnikov, MV; Pashenkov, MV; Rogovskii, VS; Sviridova, AA, 2020) |
| "Was to evaluate the effect of selective serotonin reuptake inhibitor fluoxetine on the production of cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) by dendritic cells in multiple sclerosis (MS)." | 3.96 | [The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro]. ( Boyko, AN; Krivenko, LV; Melnikov, MV; Pashenkov, MV; Rogovskii, VS; Sviridova, AA, 2020) |
| "This study was carried out to clarify the effects of the antidepressant fluoxetine, a selective serotonin reuptake inhibitor, for its potential use in autoimmune diseases like multiple sclerosis in a rat model of experimental autoimmune encephalomyelitis (EAE)." | 3.78 | Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. ( Liu, S; Liu, XJ; Lu, T; Qiu, G; Wang, X; Wu, Y; Yuan, XQ, 2012) |
| "Fluoxetine is a selective serotonin reuptake inhibitor, which also has an immunomodulatory effect." | 1.62 | The role of 5-HT ( Boyko, A; Kudrin, V; Melnikov, M; Pashenkov, M; Rogovskii, V; Sviridova, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Minarini, A | 1 |
| Rosini, M | 1 |
| Tumiatti, V | 1 |
| Recanatini, M | 1 |
| Melchiorre, C | 1 |
| Foley, P | 1 |
| Parker, RA | 2 |
| de Angelis, F | 2 |
| Connick, P | 2 |
| Chandran, S | 2 |
| Young, C | 1 |
| Weir, CJ | 2 |
| Chataway, J | 2 |
| Grech, LB | 2 |
| Butler, E | 2 |
| Stuckey, S | 2 |
| Hester, R | 2 |
| Mostert, JP | 3 |
| De Keyser, J | 3 |
| Plantone, D | 1 |
| Doshi, A | 1 |
| John, N | 1 |
| Stutters, J | 1 |
| MacManus, D | 1 |
| Prados Carrasco, F | 1 |
| Barkhof, F | 1 |
| Ourselin, S | 1 |
| Braisher, M | 1 |
| Ross, M | 1 |
| Cranswick, G | 1 |
| Pavitt, SH | 1 |
| Giovannoni, G | 1 |
| Gandini Wheeler-Kingshott, CA | 1 |
| Hawkins, C | 1 |
| Sharrack, B | 1 |
| Bastow, R | 1 |
| Stallard, N | 1 |
| Krivenko, LV | 1 |
| Sviridova, AA | 1 |
| Melnikov, MV | 1 |
| Rogovskii, VS | 1 |
| Boyko, AN | 1 |
| Pashenkov, MV | 1 |
| Sviridova, A | 1 |
| Rogovskii, V | 1 |
| Kudrin, V | 1 |
| Pashenkov, M | 1 |
| Boyko, A | 1 |
| Melnikov, M | 1 |
| Ha-Vinh, P | 1 |
| Nauleau, S | 1 |
| Clementz, M | 1 |
| Régnard, P | 1 |
| Sauze, L | 1 |
| Clavaud, H | 1 |
| Sijens, PE | 2 |
| Irwan, R | 1 |
| Potze, JH | 1 |
| Oudkerk, M | 2 |
| Patti, F | 1 |
| Leone, C | 1 |
| D'Amico, E | 1 |
| Yuan, XQ | 1 |
| Qiu, G | 1 |
| Liu, XJ | 1 |
| Liu, S | 1 |
| Wu, Y | 1 |
| Wang, X | 1 |
| Lu, T | 1 |
| Otton, SV | 1 |
| Wu, D | 1 |
| Joffe, RT | 1 |
| Cheung, SW | 1 |
| Sellers, EM | 1 |
| Nahas, Z | 1 |
| Arlinghaus, KA | 1 |
| Kotrla, KJ | 1 |
| Clearman, RR | 1 |
| George, MS | 1 |
| Shafey, H | 1 |
| Flax, JW | 1 |
| Gray, J | 1 |
| Herbert, J | 1 |
| Browning, WN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.[NCT01910259] | Phase 2 | 445 participants (Actual) | Interventional | 2014-12-18 | Completed | ||
| 5-HTSEP: Serotonin 5-HT7 Receptor Implication in the Inflammatory Mechanisms in Multiple Sclerosis[NCT04546698] | 78 participants (Actual) | Observational | 2020-09-07 | Completed | |||
| RESEPTOR 5-HT7 : Interest of the 5-HT7 Serotonin Receptor as a Biomarker in Multiple Sclerosis[NCT05746845] | 120 participants (Anticipated) | Observational | 2023-03-06 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fluoxetine and Multiple Sclerosis
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium | 2008 |
Treatment options of cognitive impairment in multiple sclerosis.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Fluoxetine; Humans; Interferon-beta; Memantine; Mult | 2010 |
3 trials available for fluoxetine and Multiple Sclerosis
| Article | Year |
|---|---|
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Topics: Adult; Amiloride; Double-Blind Method; Fluoxetine; Humans; Multiple Sclerosis; Multiple Sclerosis, C | 2022 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Flu | 2020 |
Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Aspartic Acid; Cerebral Corte | 2006 |
13 other studies available for fluoxetine and Multiple Sclerosis
| Article | Year |
|---|---|
Letter to the editor: FLOUX-PMS study sample considerations.
Topics: Demyelinating Diseases; Fluoxetine; Humans; Multiple Sclerosis | 2019 |
Response to Grech et al.: FLOUX-PMS study sample considerations.
Topics: Demyelinating Diseases; Fluoxetine; Humans; Multiple Sclerosis | 2019 |
[The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro].
Topics: Dendritic Cells; Fluoxetine; Humans; Interleukin-1beta; Interleukin-6; Multiple Sclerosis | 2020 |
The role of 5-HT
Topics: Adult; Female; Fluoxetine; Humans; Male; Multiple Sclerosis; Receptor, Serotonin, 5-HT2B; Selective | 2021 |
Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Child; Child, Preschool; Cross-Sec | 2019 |
Neuroprotective Benefits of Antidepressants in Multiple Sclerosis: Are We Missing the Mark?
Topics: Animals; Antidepressive Agents; Depression; Fluoxetine; Humans; Multiple Sclerosis; Neuroprotective | 2019 |
Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging.
Topics: Astrocytes; Axons; Brain; Diffusion Magnetic Resonance Imaging; Female; Fluoxetine; Humans; Magnetic | 2008 |
Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Encephalomyelitis, Autoimmune, Experimental; Fema | 2012 |
Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Encephalomyelitis, Autoimmune, Experimental; Fema | 2012 |
Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Encephalomyelitis, Autoimmune, Experimental; Fema | 2012 |
Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Encephalomyelitis, Autoimmune, Experimental; Fema | 2012 |
Inhibition by fluoxetine of cytochrome P450 2D6 activity.
Topics: Adult; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; | 1993 |
Rapid response of emotional incontinence to selective serotonin reuptake inhibitors.
Topics: Adult; Affective Symptoms; Aged; Brain Injuries; Cerebrovascular Disorders; Crying; Fluoxetine; Huma | 1998 |
The effect of fluoxetine in depression associated with multiple sclerosis.
Topics: Adult; Cognition Disorders; Depressive Disorder; Doxepin; Female; Fluoxetine; Humans; Multiple Scler | 1992 |
Effect of fluoxetine on patients with multiple sclerosis.
Topics: Acute Disease; Depressive Disorder; Fluoxetine; Humans; Multiple Sclerosis | 1991 |
Exacerbation of symptoms of multiple sclerosis in a patient taking fluoxetine.
Topics: Acute Disease; Adult; Depressive Disorder; Female; Fluoxetine; Humans; Multiple Sclerosis | 1990 |